Citigroup’s DexCom DXCM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.14M | Sell |
50,000
-120,000
| -71% | -$8.36M | ﹤0.01% | 2334 |
|
|
2025
Q4 | $11.3M | Buy |
170,000
+100,000
| +143% | +$6.46M | 0.01% | 1443 |
|
|
2025
Q3 | $4.71M | Buy |
70,000
+30,000
| +75% | +$2.37M | ﹤0.01% | 2013 |
|
|
2025
Q2 | $3.49M | Sell |
40,000
-80,000
| -67% | -$6.27M | ﹤0.01% | 2189 |
|
|
2025
Q1 | $8.19M | Sell |
120,000
-143,800
| -55% | -$11.7M | ﹤0.01% | 1500 |
|
|
2024
Q4 | $20.5M | Buy |
263,800
+160,000
| +154% | +$11.8M | 0.01% | 943 |
|
|
2024
Q3 | $6.96M | Sell |
103,800
-28,000
| -21% | -$2.3M | ﹤0.01% | 1570 |
|
|
2024
Q2 | $14.9M | Buy |
131,800
+68,000
| +107% | +$8.6M | 0.01% | 1041 |
|
|
2024
Q1 | $8.85M | Hold |
63,800
| – | – | 0.01% | 1325 |
|
|
2023
Q4 | $7.92M | Hold |
63,800
| – | – | 0.01% | 1330 |
|
|
2023
Q3 | $5.95M | Sell |
63,800
-24,900
| -28% | -$2.81M | ﹤0.01% | 1349 |
|
|
2023
Q2 | $11.4M | Buy |
88,700
+86,700
| +4,335% | +$10.5M | 0.01% | 1089 |
|
|
2023
Q1 | $232K | Sell |
2,000
-48,000
| -96% | -$5.37M | ﹤0.01% | 3655 |
|
|
2022
Q4 | $5.66M | Buy |
+50,000
| New | +$5.49M | ﹤0.01% | 1411 |
|
|
2021
Q1 | – | Sell |
-172,800
| Closed | -$16M | – | 6523 |
|
|
2020
Q4 | $16M | Buy |
172,800
+55,200
| +47% | +$4.93M | 0.01% | 1199 |
|
|
2020
Q3 | $12.1M | Sell |
117,600
-25,200
| -18% | -$2.63M | 0.01% | 1221 |
|
|
2020
Q2 | $14.5M | Buy |
142,800
+55,200
| +63% | +$4.94M | 0.01% | 1049 |
|
|
2020
Q1 | $5.9M | Buy |
87,600
+4,800
| +6% | +$299K | 0.01% | 1530 |
|
|
2019
Q4 | $4.53M | Buy |
82,800
+28,800
| +53% | +$1.37M | ﹤0.01% | 2110 |
|
|
2019
Q3 | $2.02M | Hold |
54,000
| – | – | ﹤0.01% | 2861 |
|
|
2019
Q2 | $2.02M | Buy |
54,000
+30,400
| +129% | +$956K | ﹤0.01% | 2837 |
|
|
2019
Q1 | $703K | Buy |
23,600
+16,400
| +228% | +$576K | ﹤0.01% | 3797 |
|
|
2018
Q4 | $216K | Sell |
7,200
-22,000
| -75% | -$698K | ﹤0.01% | 4946 |
|
|
2018
Q3 | $1.04M | Buy |
29,200
+14,800
| +103% | +$459K | ﹤0.01% | 3454 |
|
|
2018
Q2 | $342K | Buy |
14,400
+9,200
| +177% | +$195K | ﹤0.01% | 4488 |
|
|
2018
Q1 | $96K | Sell |
5,200
-13,200
| -72% | -$195K | ﹤0.01% | 5647 |
|
|
2017
Q4 | $264K | Sell |
18,400
-34,400
| -65% | -$447K | ﹤0.01% | 4777 |
|
|
2017
Q3 | $646K | Buy |
52,800
+28,800
| +120% | +$509K | ﹤0.01% | 3838 |
|
|
2017
Q2 | $439K | Buy |
24,000
+15,200
| +173% | +$281K | ﹤0.01% | 4107 |
|
|
2017
Q1 | $186K | Buy |
8,800
+3,200
| +57% | +$62.5K | ﹤0.01% | 4720 |
|
|
2016
Q4 | $84K | Buy |
5,600
+2,800
| +100% | +$49.6K | ﹤0.01% | 5876 |
|
|
2016
Q3 | $61K | Buy |
+2,800
| New | +$62.3K | ﹤0.01% | 5532 |
|
Other funds holding DXCM
VCM
VPM
Citigroup's DXCM Position: Q1 2026 in Review
Citigroup reduced its DexCom (DXCM) stake by 1.4% in Q1 2026, selling an estimated $830K and leaving 834,087 shares worth $52.4M. The position accounts for 0.02% of the portfolio, ranked #630.
Citigroup first reported a position in DXCM in Q2 2013 and has held it in 52 quarters since. The position peaked at $108M in Q4 2023. 956 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.
- Citigroup held 834,087 shares of DexCom worth $52.4M as of Q1 2026.
- Citigroup sold 11,916 DexCom shares in Q1 2026, an estimated $830K.
- DexCom made up 0.02% of Citigroup's portfolio in Q1 2026, its #630 holding.
- Citigroup first reported a position in DexCom in Q2 2013 and has held it in 52 quarters since.
- Citigroup's DexCom position peaked at $108M in Q4 2023.
- 956 funds tracked by Wall St. Rank held DexCom as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.